Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Organon Bids Farewell to 1990s Blockbusters Lipovas and Renivace in Japan
October 16, 2025
-
REGULATORY Deeper CEA Price Cuts Mooted for “Cost Increase” Products: FY2026 Reform Debate
October 16, 2025
-
REGULATORY Chuikyo Urges Stricter Pricing Rules for Conditionally Approved Regenerative Medicines
October 16, 2025
-
BUSINESS Kite Looks to Expand Japan CAR-T Footprint, Boosts Supply Infrastructure
October 15, 2025
-
REGULATORY Komeito’s Exit from Ruling Coalition Casts Uncertainty over Japan’s Drug Policy
October 15, 2025
-
REGULATORY MHLW to Clarify Criteria for Japanese PI Waivers through Q&A, Calls for Data-Based Justifications
October 14, 2025
-
REGULATORY GS1 Barcode Adoption Stalls at 40% of Hospitals, Pharmacist Urges Subsidies
October 10, 2025
-
REGULATORY Japan Launches Study on Legal Framework for Patent Linkage System
October 9, 2025
-
REGULATORY Chuikyo Frowns on Industry Calls for Scrapping Huge-Seller Re-Pricing, Spillovers
October 9, 2025
-
BUSINESS NHI-Market Price Gap Likely to Narrow Further in 2025; Will It Drop into 4% Zone?
October 8, 2025
-
BUSINESS Leqembi Iqlik Autoinjector Now Available in US: Eisai/Biogen
October 8, 2025
-
COMMENTARY Inside Eylea - 2: Will a Bio-AG Return after Six Years? Pricing Debate Resumes
October 7, 2025
-
ACADEMIA Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
-
BUSINESS Pharma Industry Generally Welcomes New LDP Leader Takaichi
October 7, 2025
-
BUSINESS Boehringer Ingelheim Taps Marc Hasson to Lead Japan Operations
October 7, 2025
-
COMMENTARY Inside Eylea - 1: Patent Issues Behind Differences in Biosimilar Indications for AMD and DME
October 6, 2025
-
BUSINESS Moderna Reaffirms Japan Commitment, Denies Downsizing Concerns
October 3, 2025
-
BUSINESS Regeneron Bolsters Japan Oncology Team as Libtayo Gains Ground
October 3, 2025
-
BUSINESS Argenx Puts Japan at Core of Global Innovation Strategy
October 3, 2025
-
BUSINESS Sanofi Sets Sights on 2026 NIP Inclusion of RSV Drug Beyfortus in Japan
October 2, 2025
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…